Fractyl Health (GUTS) Expected to Announce Earnings on Tuesday

Key Points

• Fractyl Health (NASDAQ:GUTS) is set to report Q1 2026 results after the market close on May 12, with analysts expecting ($0.17) EPS and an earnings call at 4:30 PM ET.
• The company beat expectations last quarter, reporting $0.15 EPS vs. a consensus of ($0.19), but analysts still forecast roughly ‑$1 EPS for both the current and next fiscal year.
• Shares trade around $0.69 (market cap ≈ $109.6M) with a one‑year range of $0.38–$3.03, notable hedge fund buying (e.g., Nantahala, Alyeska, Woodline, Marshall Wace), and a mixed Wall Street picture—consensus rating "Hold" with a $5.40 price target.

Fractyl Health (NASDAQ:GUTS - Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Fractyl Health to post earnings of ($0.17) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last released its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.34. On average, analysts expect Fractyl Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fractyl Health Stock Performance

NASDAQ:GUTS traded down $0.04 on Tuesday, hitting $0.69. The company's stock had a trading volume of 1,130,567 shares, compared to its average volume of 4,537,396. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 3.23. The stock has a fifty day moving average of $0.50 and a two-hundred day moving average of $1.16. The firm has a market capitalization of $109.63 million, a P/E ratio of -0.37 and a beta of 2.11. Fractyl Health has a one year low of $0.38 and a one year high of $3.03.

Hedge Funds Weigh In On Fractyl Health

A number of hedge funds have recently added to or reduced their stakes in GUTS. Nantahala Capital Management LLC bought a new position in Fractyl Health during the 3rd quarter worth $19,298,000. Alyeska Investment Group L.P. bought a new position in Fractyl Health during the 3rd quarter worth $8,981,000. Woodline Partners LP increased its stake in Fractyl Health by 821.1% during the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company's stock worth $8,755,000 after acquiring an additional 4,908,693 shares during the period. General Catalyst Group Management LLC bought a new position in Fractyl Health during the 2nd quarter worth $7,912,000. Finally, Marshall Wace LLP increased its stake in Fractyl Health by 234.9% during the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company's stock worth $13,039,000 after acquiring an additional 4,156,969 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GUTS. Morgan Stanley lowered Fractyl Health from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $8.00 to $2.00 in a research note on Thursday, January 29th. Canaccord Genuity Group restated a "buy" rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Friday, April 24th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.